Want to join the conversation?
$PRGO received U.S. FDA approval for generic version of Upsher-Smith Labs' KlorCon (potassium chloride) extended-release tablets (600 mg & 750 mg), which are marketed by $NVS. KlorCon is indicated for treatment of hypokalemia (low levels of potassium in blood). The U.S. market for the both generic and branded offerings of KlorCon is about $81MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.